Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1991 Nov;88(5):1445–1451. doi: 10.1172/JCI115453

Interleukin 1 receptor antagonist. A new member of the interleukin 1 family.

W P Arend 1
PMCID: PMC295645  PMID: 1834696

Abstract

This review has summarized recent information derived from many laboratories on the discovery, characteristics, and properties of a new member of the IL-1 family, IL-1 receptor antagonist. In addition to information, an emphasis has been placed on unanswered questions and new concepts. The existence of this first-described naturally occurring specific cytokine receptor antagonist may lead to a different perspective on the cytokine network. A major unanswered question emphasized throughout this review, that now can be addressed more directly, concerns what are the physiological roles of members of the IL-1 family. Although IL-1 beta is presumed to function primarily as an extracellular cytokine, this molecule lacks a leader peptide, is synthesized and handled by the cells in a manner suggestive of a cytoplasmic (not secretory) protein, and may only be released after cellular injury. Furthermore, although IL-1ra possesses a leader sequence, 50% or more of this protein remains cell associated. Do these observations suggest that members of the IL-1 family possess important intracellular functions, as yet undetermined? IL-1 alpha may play an intracellular role in regulating senescence; an IL-1 alpha antisense oligodeoxynucleotide was shown to prolong the life span of cultured human endothelial cells. Whether intracellular IL-1ra plays a role in influencing life span has not been determined. The discovery of IL-1ra has led to a first level of assumptions that this molecule may be functioning in vivo to regulate the pleiotropic extracellular effects of IL-1 in physiological or pathophysiological processes. Although enticing, these assumptions have not yet been proven to be true. Perhaps we need to look beyond, or within, and consider that IL-1ra and other members of the IL-1 family may have additional roles in normal or abnormal cell growth and development.

Full text

PDF
1445

Images in this article

1449Image
on p.1449

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander H. R., Doherty G. M., Buresh C. M., Venzon D. J., Norton J. A. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med. 1991 Apr 1;173(4):1029–1032. doi: 10.1084/jem.173.4.1029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arend W. P., Dayer J. M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 1990 Mar;33(3):305–315. doi: 10.1002/art.1780330302. [DOI] [PubMed] [Google Scholar]
  3. Arend W. P., Joslin F. G., Massoni R. J. Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J Immunol. 1985 Jun;134(6):3868–3875. [PubMed] [Google Scholar]
  4. Arend W. P., Joslin F. G., Thompson R. C., Hannum C. H. An IL-1 inhibitor from human monocytes. Production and characterization of biologic properties. J Immunol. 1989 Sep 15;143(6):1851–1858. [PubMed] [Google Scholar]
  5. Arend W. P., Smith M. F., Jr, Janson R. W., Joslin F. G. IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently. J Immunol. 1991 Sep 1;147(5):1530–1536. [PubMed] [Google Scholar]
  6. Arend W. P., Welgus H. G., Thompson R. C., Eisenberg S. P. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest. 1990 May;85(5):1694–1697. doi: 10.1172/JCI114622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Balavoine J. F., de Rochemonteix B., Williamson K., Seckinger P., Cruchaud A., Dayer J. M. Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J Clin Invest. 1986 Oct;78(4):1120–1124. doi: 10.1172/JCI112669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bienkowski M. J., Eessalu T. E., Berger A. E., Truesdell S. E., Shelly J. A., Laborde A. L., Zurcher-Neely H. A., Reardon I. M., Heinrikson R. L., Chosay J. G. Purification and characterization of interleukin 1 receptor level antagonist proteins from THP-1 cells. J Biol Chem. 1990 Aug 25;265(24):14505–14511. [PubMed] [Google Scholar]
  9. Carter D. B., Deibel M. R., Jr, Dunn C. J., Tomich C. S., Laborde A. L., Slightom J. L., Berger A. E., Bienkowski M. J., Sun F. F., McEwan R. N. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature. 1990 Apr 12;344(6267):633–638. doi: 10.1038/344633a0. [DOI] [PubMed] [Google Scholar]
  10. Chang T. L., Shea C. M., Urioste S., Thompson R. C., Boom W. H., Abbas A. K. Heterogeneity of helper/inducer T lymphocytes. III. Responses of IL-2- and IL-4-producing (Th1 and Th2) clones to antigens presented by different accessory cells. J Immunol. 1990 Nov 1;145(9):2803–2808. [PubMed] [Google Scholar]
  11. Cominelli F., Nast C. C., Clark B. D., Schindler R., Lierena R., Eysselein V. E., Thompson R. C., Dinarello C. A. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest. 1990 Sep;86(3):972–980. doi: 10.1172/JCI114799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dayer-Métroz M. D., Wollheim C. B., Seckinger P., Dayer J. M. A natural interleukin 1 (IL-1) inhibitor counteracts the inhibitory effect of IL-1 on insulin production in cultured rat pancreatic islets. J Autoimmun. 1989 Apr;2(2):163–171. doi: 10.1016/0896-8411(89)90152-2. [DOI] [PubMed] [Google Scholar]
  13. Dinarello C. A. Interleukin-1 and interleukin-1 antagonism. Blood. 1991 Apr 15;77(8):1627–1652. [PubMed] [Google Scholar]
  14. Dripps D. J., Brandhuber B. J., Thompson R. C., Eisenberg S. P. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem. 1991 Jun 5;266(16):10331–10336. [PubMed] [Google Scholar]
  15. Eisenberg S. P., Brewer M. T., Verderber E., Heimdal P., Brandhuber B. J., Thompson R. C. Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: evolution of a cytokine control mechanism. Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5232–5236. doi: 10.1073/pnas.88.12.5232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Eisenberg S. P., Evans R. J., Arend W. P., Verderber E., Brewer M. T., Hannum C. H., Thompson R. C. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature. 1990 Jan 25;343(6256):341–346. doi: 10.1038/343341a0. [DOI] [PubMed] [Google Scholar]
  17. Galve-de Rochemonteix B., Nicod L. P., Junod A. F., Dayer J. M. Characterization of a specific 20- to 25-kD interleukin-1 inhibitor from cultured human lung macrophages. Am J Respir Cell Mol Biol. 1990 Oct;3(4):355–361. doi: 10.1165/ajrcmb/3.4.355. [DOI] [PubMed] [Google Scholar]
  18. Gehrke L., Jobling S. A., Paik L. S., McDonald B., Rosenwasser L. J., Auron P. E. A point mutation uncouples human interleukin-1 beta biological activity and receptor binding. J Biol Chem. 1990 Apr 15;265(11):5922–5925. [PubMed] [Google Scholar]
  19. Granowitz E. V., Clark B. D., Mancilla J., Dinarello C. A. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem. 1991 Aug 5;266(22):14147–14150. [PubMed] [Google Scholar]
  20. Hannum C. H., Wilcox C. J., Arend W. P., Joslin F. G., Dripps D. J., Heimdal P. L., Armes L. G., Sommer A., Eisenberg S. P., Thompson R. C. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature. 1990 Jan 25;343(6256):336–340. doi: 10.1038/343336a0. [DOI] [PubMed] [Google Scholar]
  21. Haskill S., Martin G., Van Le L., Morris J., Peace A., Bigler C. F., Jaffe G. J., Hammerberg C., Sporn S. A., Fong S. cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3681–3685. doi: 10.1073/pnas.88.9.3681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Henderson B., Thompson R. C., Hardingham T., Lewthwaite J. Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist. Cytokine. 1991 May;3(3):246–249. doi: 10.1016/1043-4666(91)90023-7. [DOI] [PubMed] [Google Scholar]
  23. Henricson B. E., Neta R., Vogel S. N. An interleukin-1 receptor antagonist blocks lipopolysaccharide-induced colony-stimulating factor production and early endotoxin tolerance. Infect Immun. 1991 Mar;59(3):1188–1191. doi: 10.1128/iai.59.3.1188-1191.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Ju G., Labriola-Tompkins E., Campen C. A., Benjamin W. R., Karas J., Plocinski J., Biondi D., Kaffka K. L., Kilian P. L., Eisenberg S. P. Conversion of the interleukin 1 receptor antagonist into an agonist by site-specific mutagenesis. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2658–2662. doi: 10.1073/pnas.88.7.2658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Larrick J. W. Native interleukin 1 inhibitors. Immunol Today. 1989 Feb;10(2):61–66. doi: 10.1016/0167-5699(89)90308-3. [DOI] [PubMed] [Google Scholar]
  26. Maier J. A., Voulalas P., Roeder D., Maciag T. Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer. Science. 1990 Sep 28;249(4976):1570–1574. doi: 10.1126/science.2218499. [DOI] [PubMed] [Google Scholar]
  27. Malyak M., Joslin F. G., Verderber E. L., Eisenberg S. P., Arend W. P. IL-1ra ELISA: reduction and alkylation of synovial fluid eliminates interference by IgM rheumatoid factors. J Immunol Methods. 1991 Jul 5;140(2):281–288. doi: 10.1016/0022-1759(91)90381-o. [DOI] [PubMed] [Google Scholar]
  28. Mazzei G. J., Bernasconi L. M., Lewis C., Mermod J. J., Kindler V., Shaw A. R. Human granulocyte-macrophage colony-stimulating factor plus phorbol myristate acetate stimulate a promyelocytic cell line to produce an IL-1 inhibitor. J Immunol. 1990 Jul 15;145(2):585–591. [PubMed] [Google Scholar]
  29. Mazzei G. J., Seckinger P. L., Dayer J. M., Shaw A. R. Purification and characterization of a 26-kDa competitive inhibitor of interleukin 1. Eur J Immunol. 1990 Mar;20(3):683–689. doi: 10.1002/eji.1830200332. [DOI] [PubMed] [Google Scholar]
  30. McIntyre K. W., Stepan G. J., Kolinsky K. D., Benjamin W. R., Plocinski J. M., Kaffka K. L., Campen C. A., Chizzonite R. A., Kilian P. L. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med. 1991 Apr 1;173(4):931–939. doi: 10.1084/jem.173.4.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Ohlsson K., Björk P., Bergenfeldt M., Hageman R., Thompson R. C. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature. 1990 Dec 6;348(6301):550–552. doi: 10.1038/348550a0. [DOI] [PubMed] [Google Scholar]
  32. Olds L. C., Miller J. J., 3rd C3 activation products correlate with antibodies to lipid A in pauciarticular juvenile arthritis. Arthritis Rheum. 1990 Apr;33(4):520–524. doi: 10.1002/art.1780330409. [DOI] [PubMed] [Google Scholar]
  33. Opp M. R., Krueger J. M. Interleukin 1-receptor antagonist blocks interleukin 1-induced sleep and fever. Am J Physiol. 1991 Feb;260(2 Pt 2):R453–R457. doi: 10.1152/ajpregu.1991.260.2.R453. [DOI] [PubMed] [Google Scholar]
  34. Poutsiaka D. D., Clark B. D., Vannier E., Dinarello C. A. Production of interleukin-1 receptor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated. Blood. 1991 Sep 1;78(5):1275–1281. [PubMed] [Google Scholar]
  35. Prieur A. M., Kaufmann M. T., Griscelli C., Dayer J. M. Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet. 1987 Nov 28;2(8570):1240–1242. doi: 10.1016/s0140-6736(87)91854-x. [DOI] [PubMed] [Google Scholar]
  36. Roux-Lombard P., Modoux C., Dayer J. M. Production of interleukin-1 (IL-1) and a specific IL-1 inhibitor during human monocyte-macrophage differentiation: influence of GM-CSF. Cytokine. 1989 Nov;1(1):45–51. doi: 10.1016/1043-4666(89)91047-8. [DOI] [PubMed] [Google Scholar]
  37. Schur P. H., Chang D. M., Baptiste P., Uhteg L. C., Hanson D. C. Human monocytes produce IL-1 and an inhibitor of IL-1 in response to two different signals. Clin Immunol Immunopathol. 1990 Oct;57(1):45–63. doi: 10.1016/0090-1229(90)90021-h. [DOI] [PubMed] [Google Scholar]
  38. Seckinger P., Klein-Nulend J., Alander C., Thompson R. C., Dayer J. M., Raisz L. G. Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol. 1990 Dec 15;145(12):4181–4184. [PubMed] [Google Scholar]
  39. Seckinger P., Lowenthal J. W., Williamson K., Dayer J. M., MacDonald H. R. A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol. 1987 Sep 1;139(5):1546–1549. [PubMed] [Google Scholar]
  40. Seckinger P., Williamson K., Balavoine J. F., Mach B., Mazzei G., Shaw A., Dayer J. M. A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha. J Immunol. 1987 Sep 1;139(5):1541–1545. [PubMed] [Google Scholar]
  41. Seckinger P., Yaron I., Meyer F. A., Yaron M., Dayer J. M. Modulation of the effects of interleukin-1 on glycosaminoglycan synthesis by the urine-derived interleukin-1 inhibitor, but not by interleukin-6. Arthritis Rheum. 1990 Dec;33(12):1807–1814. doi: 10.1002/art.1780331208. [DOI] [PubMed] [Google Scholar]
  42. Shields J., Bernasconi L. M., Benotto W., Shaw A. R., Mazzei G. J. Production of a 26,000-dalton interleukin 1 inhibitor by human monocytes is regulated by granulocyte-macrophage colony-stimulating factor. Cytokine. 1990 Mar;2(2):122–128. doi: 10.1016/1043-4666(90)90006-f. [DOI] [PubMed] [Google Scholar]
  43. Smith R. J., Chin J. E., Sam L. M., Justen J. M. Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum. 1991 Jan;34(1):78–83. doi: 10.1002/art.1780340112. [DOI] [PubMed] [Google Scholar]
  44. Spinas G. A., Bloesch D., Kaufmann M. T., Keller U., Dayer J. M. Induction of plasma inhibitors of interleukin 1 and TNF-alpha activity by endotoxin administration to normal humans. Am J Physiol. 1990 Nov;259(5 Pt 2):R993–R997. doi: 10.1152/ajpregu.1990.259.5.R993. [DOI] [PubMed] [Google Scholar]
  45. Turner M., Chantry D., Katsikis P., Berger A., Brennan F. M., Feldmann M. Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-beta. Eur J Immunol. 1991 Jul;21(7):1635–1639. doi: 10.1002/eji.1830210708. [DOI] [PubMed] [Google Scholar]
  46. Ulich T. R., Yin S. M., Guo K. Z., del Castillo J., Eisenberg S. P., Thompson R. C. The intratracheal administration of endotoxin and cytokines. III. The interleukin-1 (IL-1) receptor antagonist inhibits endotoxin- and IL-1-induced acute inflammation. Am J Pathol. 1991 Mar;138(3):521–524. [PMC free article] [PubMed] [Google Scholar]
  47. Wakabayashi G., Gelfand J. A., Burke J. F., Thompson R. C., Dinarello C. A. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J. 1991 Mar 1;5(3):338–343. doi: 10.1096/fasebj.5.3.1825816. [DOI] [PubMed] [Google Scholar]
  48. Yamayoshi M., Ohue M., Kawashima H., Kotani H., IIda M., Kawata S., Yamada M. A human IL-1 alpha derivative which lacks prostaglandin E2 inducing activity and inhibits the activity of IL-1 through receptor competition. Lymphokine Res. 1990 Fall;9(3):405–413. [PubMed] [Google Scholar]
  49. Zahedi K., Seldin M. F., Rits M., Ezekowitz R. A., Whitehead A. S. Mouse IL-1 receptor antagonist protein. Molecular characterization, gene mapping, and expression of mRNA in vitro and in vivo. J Immunol. 1991 Jun 15;146(12):4228–4233. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES